RxDoctor Payments DataLook up a doctor →

Paul Guichard, DO

Interventional Cardiology · Marietta, GANPI 1649269796

Payments from drug & device makers

$377,396in general payments, 2019–2025

Across 665 payments — averaging $567.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$105K
  • Actelion Pharmaceuticals US, Inc.$95K
  • Penumbra, Inc.$87K
  • Bayer$31K
  • Merck$30K
  • Actelion Pharmaceuticals, Ltd$11K
  • plus $18K from 33 others

What the payments were for

  • Consulting fees$16,2806%
  • Speaking & faculty fees$203,47178%
  • Travel & lodging$19,9828%
  • Food & beverage$20,6468%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$377,396 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$213,111
Medicare patients
878
Services billed
2,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan127$1,601,746
AdempasRiociguat100$1,407,641
UptraviSelexipag37$849,684
Tyvaso DpiTreprostinil30$700,329
EliquisApixaban492$591,049
FarxigaDapagliflozin Propanediol115$111,776
JardianceEmpagliflozin83$99,945
XareltoRivaroxaban55$70,391
EntrestoSacubitril/Valsartan54$60,394
Ambrisentan21$47,655
Repatha SureclickEvolocumab24$25,204
Praluent PenAlirocumab25$16,604
Sildenafil Citrate52$13,940
BrilintaTicagrelor25$13,296
Ranolazine ErRanolazine126$13,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$95,312$2,451,430164 claims
BayerAdempas$31,214$1,407,641100 claims
PfizerEliquis$500$591,049492 claims
AstraZenecaFarxiga, Brilinta$301$125,072140 claims
Boehringer IngelheimJardiance$122$99,94583 claims
Johnson & JohnsonXarelto$73$70,39155 claims
NovartisEntresto$690$60,39454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →